Range of solutions

We were the first in the world to develop fully automated antigen qualitative and antigen quantitative test reagents. Third-party studies have proven our reagents to be compatible with other companies’ products, and they have highlighted our assays as having the highest detection sensitivity on the market. We now offer various testing solutions that are used across the world today to support fast and trustworthy diagnosis.

Since the first days of the pandemic, the H.U. Group has been engaging in clinical laboratory testing and has supported those fighting at the front lines of the COVID-19 pandemic. In order to support people who are confronting the pandemic, both in Japan and globally, the H.U. Group is taking efforts to prevent the spread of COVID-19 by mobilizing our technologies, improving and expanding PCR testing, and developing and stably supplying various antigen and antibody testing solutions.

Our products are widely used at university hospitals, testing centers, and airport quarantines. Currently, a total of more than 50 high-sensitivity quantitative antigen testing systems are, for instance, in operation at eight airports in Japan, and large-scale and fully automated antigen testing is performed at a number of international airports in Germany using Fujirebio testing solutions.

Preparing for a future crisis

With the expectation of new variants continuously occurring in the future, we believe that it is extremely important to monitor mutations which might affect the testing accuracy, and continuously improve testing techniques in order to detect the variant correctly.

On a daily basis we will continue our own research and will monitor and improve the PCR and antigen tests provided by the H.U. Group to detect any new variants.

Browse our COVID-19 testing offer

We offer various testing solutions that are used across the world today to support fast and trustworthy diagnosis. 

See all COVID-19 related resources and products here